Teva Pharmaceutical Industries Limited has been making significant strides in the biotech industry. The company witnessed substantial
stock market gains, hitting a 52-week high of $22.52.
Hennessy Advisors Inc., Hennion & Walsh Asset Management Inc., Redhawk Wealth Advisors Inc., PFW Advisors LLC and
First Hawaiian Bank increased their holdings in the company's shares.
Assenagon Asset Management S.A. and
Tidal Investments LLC sold a portion of their holdings. Even Roberto Mignone, a director at Teva, sold 286,000 shares.
Piper Sandler has increased Teva’s price target to $30.00. Teva's strong performance was spurred by various achievements, including the successful Phase 2b study on
the IBD drug Duvakitug, which drove an impressive 19% surge in the stock. Despite a 7% drop in the stock, Teva reported strong sales and a Q3 earnings beat, leading to a guidance increase. The company is receiving a boost from its latest
partnership with Sanofi which created a surge in both stocks. Regulatory setbacks such as losing a US appeal to keep inhaler patents on FDA protected drug list haven't significantly affected the bullish outlook.
Teva Pharmaceutical Stocks News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sat, 18 Jan 2025 14:00:21 GMT -
Rating 8
- Innovation 3
- Information 7
- Rumor -4
